Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index; none of the 58 sources its claims cite is checked for support yet.
Abstract
Retinal ganglion cells (RGCs) serve as the connection between the eye and the brain, with this connection disrupted in glaucoma. Numerous cellular mechanisms have been associated with glaucomatous neurodegeneration, and useful cellular models of glaucoma allow for the precise analysis of degenerative phenotypes. Human pluripotent stem cells (hPSCs) serve as powerful tools for studying human disease, particularly cellular mechanisms underlying neurodegeneration. Thus, efforts focused upon hPSCs with an E50K mutation in the Optineurin (OPTN) gene, a leading cause of inherited forms of glaucoma. CRISPR/Cas9 gene editing introduced the OPTN(E50K) mutation into existing lines of hPSCs, as well as generating isogenic controls from patient-derived lines. RGCs differentiated from OPTN(E50K) hPSCs exhibited numerous neurodegenerative deficits, including neurite retraction, autophagy dysfunction, apoptosis, and increased excitability. These results demonstrate the utility of OPTN(E50K) RGCs as an in vitro model of neurodegeneration, with the opportunity to develop novel therapeutic approaches for glaucoma.
Overview
CoChat Summary
TL;DR
CRISPR/Cas9 was used to introduce or correct the glaucoma-associated OPTN(E50K) mutation in human pluripotent stem cells, and RGCs derived from three-dimensional retinal organoids were characterized over maturation. OPTN(E50K) RGCs showed neurodegenerative phenotypes including neurite retraction, autophagy dysfunction, apoptosis, and increased excitability.
Key findings
- Early retinal differentiation was comparable between OPTN(E50K) and isogenic controls: no significant differences in PAX6, CHX10, BRN3B:tdTomato, RBPMS, or SNCG, with similar RGC numbers (n = 5 separate differentiation experiments).
- By 4 weeks after RGC purification, OPTN(E50K) RGCs had significantly fewer ordered neurites and branch points, shorter neurites, and smaller soma; BRN3B and ISL1 were significantly decreased relative to MAP2/DAPI, while MAP2, CHX10, recoverin, and OTX2 populations were not significantly changed (n = 3–4 separate differentiation experiments).
- Patch-clamp recordings showed no significant resting membrane potential difference, but OPTN(E50K) RGCs had significantly lower cell capacitance, higher input resistance, lower action potential current threshold, and fired significantly more action potentials (n = 2 differentiations; H7 n = 28 technical replicates, H7(E50K) n = 46 technical replicates).
- RNA sequencing found 75 downregulated and 117 upregulated genes in OPTN(E50K) RGCs (p < 0.05), with pathways related to autophagy and neurite outgrowth; OPTN(E50K) organoids showed inner-layer LC3 accumulation and increased active caspase-3, both reduced by rapamycin (2 μM, 24 h).
Methods
- CRISPR/Cas9 homology-directed repair introduced OPTN(E50K) into H7BRN3B:tdTomatoThy1.2 hESCs and corrected the mutation in patient-derived hiPSCs; clones were screened by Hpy188III digestion and Sanger sequencing, with normal karyotypes confirmed.
- hPSCs were differentiated into three-dimensional retinal organoids; at day 45, RGCs were purified by Thy1.2 MACS, plated on poly-D-ornithine/laminin, and maintained up to 4 weeks in BrainPhys medium.
- Analyses included immunocytochemistry, ImageJ/NeuronJ neurite and soma quantification, whole-cell patch-clamp electrophysiology, and RNA sequencing with DESeq2 and pathway enrichment (GEO accession GSE145069); statistics used t tests or one-way ANOVA with Tukey’s post hoc test.
Limitations
- Stated: BRN3B:tdTomato reporter downregulation at advanced OPTN(E50K) RGC stages may mean recorded phenotypes represent an earlier degenerative stage, and future experiments using fluorescent reporters must account for this downregulation.
- Evident: the paper has no dedicated limitations section; electrophysiology was limited to n = 2 differentiation experiments (H7 and H7(E50K)), and several assays used n = 3–5 differentiation experiments, so broader cell-line and differentiation-batch variability is not fully addressed.
- Evident: the study examines only the OPTN(E50K) mutation, so findings may not generalize to other glaucoma-associated mutations or patient backgrounds.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
0 Valid · 0 Not valid · 23 Not checked · 64 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No significant differences were observed in the percentage of MAP2-positive cells between OPTN(E50K) and isogenic control RGCs; however, the colocalization of either BRN3B or ISL1 with MAP2 was significantly reduced in the OPTN(E50K) condition.”
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Results > OPTN(E50K) Glaucomatous RGCs Demonstrate Morphological Deficits and Gene Downregulation after Prolonged Culture
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Representative inverted fluorescent images (Figures 3A–3H) and neurite tracings (Figures 3I–3P) of OPTN(E50K) and isogenic control RGCs revealed high degrees of similarity in neuronal maturation from 1 to 3 weeks after purification.”
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Results > OPTN(E50K) Glaucomatous RGCs Demonstrate Morphological Deficits and Gene Downregulation after Prolonged Culture
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Conversely, at later stages of RGC maturation, OPTN(E50K) RGCs demonstrated numerous characteristics associated with glaucomatous neurodegeneration, including neurite retraction, autophagy dysfunction, and increased excitability.”
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Introduction
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Initial analysis demonstrated 75 downregulated genes and 117 upregulated genes associated with OPTN(E50K) RGCs when compared with isogenic control RGCs (Figure 6B).”
- Also stated in: § RNA Sequencing Demonstrated Differential Gene Expression in OPTN(E50K) RGCs · boosted
“Differential gene expression analysis demonstrated 75 downregulated genes and 117 upregulated genes in OPTN(E50K) RGCs when compared with isogenic control RGCs (p < 0.05).”
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Results > RNA Sequencing Demonstrated Differential Gene Expression in OPTN(E50K) RGCs
boostedstates an associationn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RNA Sequencing Demonstrated Differential Gene Expression in OPTN(E50K) RGCs · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Conversely, at later stages of RGC maturation, OPTN(E50K) RGCs demonstrated numerous characteristics associated with glaucomatous neurodegeneration, including neurite retraction, autophagy dysfunction, and increased excitability.”
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Introduction
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 87 claims and to verify the 57 references still open.
- It may state two separate claims as one. 20
- The quote only partly states this claim. 1
- Probably not a substantial claim. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retinal organoid differentiation and RGC isolation were performed following our previously established protocols (17, 18).”
From A human pluripotent stem cell triculture platform to elucidate microglial regulation of retinal ganglion cells in neuroinflammation (2026) · cites this paper as [17]
In the citing paper
“we then explored prior RNA-seq data comparing isogenic control and OPTN(E50K) RGCs taken after just 10 days of maturation [12], and found a significant reduction in the expression of some other mTOR-associated genes (Fig. 3N).”
In the citing paper
“We have demonstrated that OPTN(E50K) RGCs exhibit morphological and functional deficits as soon as 4 weeks after the purification and maturation from retinal organoids (Fig. 5A–C) [12].”
In the citing paper
“We have previously demonstrated that hPSC-derived RGCs can exhibit neurodegenerative phenotypes with a glaucoma-associated OPTN(E50K) mutation [11, 12]”
In the citing paper
“we and others have developed human RGCs derived from hPSCs as a translationally relevant resource [10–14]”
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Results > RNA Sequencing Demonstrated Differential Gene Expression in OPTN(E50K) RGCs
“(C) Pathway analysis revealed a variety of upregulated and downregulated pathways associated with glaucomatous neurodegeneration (p < 0.1).”
§ Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids > Experimental Procedures > RNA Sequencing Preparation and Analysis
“Pathway enrichment analysis were conducted by hypergeometric test against human gene ontology and MsigDB v.6 canonical pathways, with p < 0.01 as the significant cutoff (Subramanian et al., 2005).”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Inagaki, 2018, Effect of timolol on optineurin aggregation in transformed induced pluripotent stem cells derived from patient with familial glaucoma, Invest. Ophthalmol. Vis. Sci., 59, 2293, 10.1167/iovs.17-22975”
Cited work 10.1167/iovs.17-22975 · retracted 2020-11-02 · notice 10.1167/iovs.61.13.18 · this paper published 2020-07
Citations
Cites
1 retracted
Inagaki, S., Kawase, K., Funato, M., Seki, J., Kawase, C., Ohuchi, K., Kameyama, T., Ando, S., Sato, A., Morozumi, W., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22975 · Cited by 13
RetractedModerated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Self-formation of optic cups and storable stratified neural retina from human ESCs
Nakano, T., Ando, S., Takata, N., Kawada, M., Muguruma, K., Sekiguchi, K., Saito, K., Yonemura, S., Eiraku, M., & Sasai, Y. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.009 · Cited by 1,447
Quigley, H. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61423-7 · Cited by 1,121
Adult-Onset Primary Open-Angle Glaucoma Caused by Mutations in Optineurin
Rezaie, T., Child, A., Hitchings, R., Brice, G., Miller, L., Coca-Prados, M., Héon, E., Krupin, T., Ritch, R., Kreutzer, D., et al. (2002) · Science · doi:10.1126/science.1066901 · Cited by 1,105
Cited by
Items 101–108 of 108
Kanno, S., Yamashita, M., Sato, K., & Nakazawa, T. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00694
Moksha, L., Zhu, Y., Salowe, R., Vrathasha, V., Nair, R. M., He, J., Halimitabrizi, M., Rice, G., Quinn, P. M. J., Cheng, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1893993
Li, J., & Yang, J. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111277
Knoblich, P. J. A., Ming, G., & Temple, S. (2026) · Neuron · doi:10.1016/j.neuron.2026.10.014
Zelt, E. P., Singh, S., Seiler, M. J., Hu, H., Atala, A., Ma, J.-X., & Zhang, Y. (2026) · Organoids · doi:10.3390/organoids5040039
Su, T., Liang, L., Zhang, L., Wang, J., Chen, L., Su, C., Cao, J., Yu, Q., Deng, S., Chan, H. F., et al. (2022) · doi:10.3389/fbioe.2022.939774.s001
Adornetto, A., Benfatto, E., Martucci, A., Bagetta, G., Nucci, C., & Russo, R. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06338-1
Metadata
- Authors
- VanderWall, K. B., Huang, K.-C., Pan, Y., Lavekar, S. S., Fligor, C. M., Allsop, A. R., Lentsch, K. A., Dang, P., Zhang, C., Tseng, H. C., Cummins, T. R., & Meyer, J. S.
- Affiliations
- Indiana University – Purdue University Indianapolis (US)
- Indiana University School of Medicine (US)
- Duke Medical Center (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Meyer, Jason S.
- ORCID
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 15
- Issue
- 1
- Pages
- 52-66
- ISSN
- 2213-6711 (ISSN-L)
- PMC
- PMC7363877
- OpenAlex
- W3034201929
- Cited by
- 108
- References
- 67
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 23 · 2023: 17 · 2022: 10 · 2021: 18 · 2020: 5
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Locations
- Stem Cell Reports (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- National Institutes of Health
- National Eye Institute (R01 EY024984, R21 EY031120)
- National Center for Advancing Translational Sciences
- Indiana State Department of Health
- Brain Injury Research Center (26343)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- glaucoma, retinal ganglion cells, optineurin, neurodegeneration, retinal organoids, human pluripotent stem cells, CRISPR/Cas9 genome editing, isogenic controls, neurite retraction, autophagy dysfunction, apoptosis, neuronal excitability, in vitro disease model
- MeSH terms
- Gene Editing, Animals, Autophagy, Cell Differentiation, Disease Models, Animal, Glaucoma, Humans, Microtubule-Associated Proteins, Mutation, Nerve Degeneration, Organoids, Phenotype, Retinal Ganglion Cells, Down-Regulation, Apoptosis, Sequence Analysis, RNA, Cell Cycle Proteins, Membrane Transport Proteins, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.